Current Report Filing (8-k)
02 September 2020 - 3:28AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 1, 2020
Hepion Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
|
Delaware
|
001-36856
|
46-2783806
|
|
(State or other jurisdiction
|
(Commission
|
IRS Employer
|
|
of incorporation or organization)
|
File Number)
|
Identification No.)
|
|
|
|
|
|
|
399 Thornall Street,
First Floor
|
|
|
|
Edison, NJ 08837
|
|
|
|
(Address of principal
executive offices)
|
|
Registrant’s telephone number, including
area code: (732) 902-4000
(Former name or former address, if changed
since last report)
Securities registered pursuant to Section 12(b) of
the Act:
|
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
|
Common Stock
|
|
HEPA
|
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether
the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth
company x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
On
September 1, 2020, Hepion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing
that CRV431 dosing has now been completed in all subjects enrolled in the Phase 1b multiple ascending dose study of CRV431. A
copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
|
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: September 1, 2020
|
|
HEPION PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Robert Foster
|
|
|
Robert Foster
|
|
|
Chief Executive Officer
|
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Nov 2023 to Nov 2024
